By Lisa Kerner
Charlotte, N.C., Oct. 2 - Heidelberg Pharma GmbH raised $20 million in a series B financing.
HDP Beteiligungs GmbH led the round, increasing its stake in the company to roughly 86%.
Proceeds will be used for ongoing clinical development programs, including confirmation of positive preliminary phase 2 findings with Fosfluridine for the treatment of actinic keratosis.
Including an earlier series A round, Heidelberg Pharma has raised a total of $52 million, according to a company news release.
In related news, shareholders agreed to change the legal form of the company to a corporation and increased the share capital to 8,722,000 shares.
Heidelberg Pharma is a drug-development company based in Ladenburg, Germany.
| Issuer: | Heidelberg Pharma GmbH
|
| Issue: | Series B financing
|
| Amount: | $20 million
|
| Investor: | HDP Beteiligungs GmbH
|
| Amount: | $20 million
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
